← Eichor
Study identifier: NCT04526353 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Early Oxybutinin Treatment for Boys With Posterior Urethral Valves

Condition: Male Urogenital Diseases  ·  Sponsor: University Hospital, Bordeaux

PhasePhase 2
Planned participants50
Who can joinMale, 3 Months to 6 Months
Healthy volunteersNo

About this study

Boys with posterior urethral valves have bladder dysfunction of varying severity. Early treatment of these children with anticholinergics is recommended by some teams, although there have never been any clear studies on the subject. To our knowledge, no comparative study of the evolution of valve bladders with or without treatment has been carried out to date. Anticholinergic treatment, although it may be beneficial in patients with abnormal bladder function, such as the neurologic bladders ( in Spina Bifida) for example, may have side effects and may not be of benefit for this valve population. The evolution of the valves could be spontaneously favorable. This study would be the first randomized clinical trial of early therapeutic drug intervention in the posterior urethral valve population.

This description comes directly from the study's public registry record.

Talk to the study team

Luke L HARPER, MD  ·  05 56 79 56 17  ·  luke.harper@chu-bordeaux.fr

Aurore A CAPELLI, PhD  ·  05 57 82 08 77  ·  aurore.capelli@chu-bordeaux.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de BordeauxBordeaux, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04526353